106567195This is a routine compliance filing designating Mr. Ashish Maheshwari (Chairman & MD) and Mr. Aman Purohit (Company Secretary & Compliance Officer) as authorised KMPs to assess and disclose material events to stock exchanges. This is a regulatory housekeeping requirement under SEBI LODR Regulations, not a business development or financial event.
This filing carries no direct investment implication and is unlikely to influence the stock price. It merely confirms the governance structure for regulatory disclosures, which is a standard periodic compliance obligation for listed companies. Investors should not read any operational or financial significance into this announcement.
High impact event - Company Name: Balaxi Pharmaceuticals Limited - Event: Board authorises KMPs under SEBI LODR Regulation 30(5) for materiality determination and stock exchange disclosures - Time: March 25, 2026 Key Insight: This is a routine compliance filing designating Mr. Ashish Maheshwari (Chairman & MD) and Mr. Aman Purohit (Company Secretary & Compliance Officer) as authorised KMPs to assess and disclose material events to stock exchanges. This is a regulatory housekeeping requirement under SEBI LODR Regulations, not a business development or financial event. Why it matters: This filing carries no direct investment implication and is unlikely to influence the stock price. It merely confirms the governance structure for regulatory disclosures, which is a standard periodic compliance obligation for listed companies. Investors should not read any operational or financial significance into this announcement. Market cap: ₹98.38 Cr sector: Pharmaceuticals confidence score: 0.05 Source: NSE Corporate Announcement Link: https://www.nseindia.com/companies-listing/corporate-filings-announcements